Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Arnhem – page 11

172 clinical trials in Arnhem, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Arnhem at a glance
172
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

172 trials in Arnhem

Open in trial search

Prostate cancer

Not recruiting

Study on the Effect of Adding Leuprorelin Acetate to Radiotherapy for Patients with Oligo-recurrent Prostate Cancer with Up to 4 Metastases

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Leuprorelin Acetate
  • Sponsor:Universitair Medisch Centrum Groningen

Multiple sclerosis

Not recruiting

Study on Personalized Dosing of Natalizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Natalizumab
  • Sponsor:Amsterdam UMC Stichting

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Naronapride Dihydrochloride Trihydrate
  • Sponsor:Dr. Falk Pharma GmbH

Acute myeloid leukaemia+1

Not recruiting

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Gilteritinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of reduced pembrolizumab dosing compared to standard dose in patients with advanced non-small cell lung cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Stichting Radboud universitair medisch centrum

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Cough

Not recruiting

Study on the Effects of Camlipixant in Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Camlipixant
  • Sponsor:Bellus Health Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing Two Treatment Sequences of CDK4/6 Inhibitors (Abemaciclib, Palbociclib, or Ribociclib) in Hormone Receptor Positive Advanced Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BOOG Study Center B.V.

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Arnhem

What the registry says about research in the country

01 Oncology Studies

Innovative research focusing on advanced gastric cancer, bladder cancer, and various forms of leukemia. Studies include evaluation of novel imaging techniques and combination therapies for better treatment outcomes.

  • Gastric Cancer Staging
  • Bladder Cancer Therapeutics
  • Acute Myeloid Leukemia Treatment

Multiple trials exploring targeted therapies and innovative diagnostic approaches for various cancer types.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management and prevention, including research on post-stroke care and cardiac arrest treatments.

  • Stroke Treatment Protocols
  • Cardiac Arrest Management
  • Cardiovascular Risk Reduction

Focus on improving patient outcomes through innovative therapeutic approaches and prevention strategies.

03 Metabolic Disorders

Clinical investigations targeting obesity and weight management, with emphasis on new therapeutic agents and their cardiovascular safety profiles.

  • Weight Management Therapies
  • Metabolic Disease Treatment
  • Safety Assessments

Evaluating novel approaches to treating metabolic disorders and their associated complications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.